Foghorn Therapeutics Inc (FHTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $124.12M
Last updated: Nov 17, 2026 at 4:26 PM ET
Foghorn Therapeutics Inc (FHTX) Statistics
Foghorn Therapeutics (FHTX) has a market cap of $124.12M and an enterprise value of $43.82M. Revenue grew 357.33% over the last 12 months from the 12 months before. Its share count is up 13.38% from a year earlier.
Total Valuation
Enterprise value is 64.70% below the market cap, as cash exceeds debt.
| Market Cap | $124.12M |
|---|---|
| Enterprise Value | $43.82M |
| Latest price (Nov 17, 2026) | $1.83 |
Key Dates
The next earnings report is expected on Mar 9, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 9, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 9, 2026 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 1.2x.
| P/E Ratio | 41.0x |
|---|---|
| P/S Ratio | 1.2x |
| Forward P/S | 1.2x |
Enterprise Valuation
Counting debt and cash, the company is valued at 21.1x EBITDA.
| EV / Earnings | 4.7x |
|---|---|
| EV / Sales | 0.4x |
| EV / EBITDA | 21.1x |
Price Statistics
The stock is down 60.98% over 52 weeks and trades 31.20% below its 50-day average.
| Beta (1Y) | 1.75 |
|---|---|
| 52-Week Change | -60.98% |
| 1-Month Change | -2.14% |
| 3-Month Change | -74.08% |
| 6-Month Change | -49.17% |
| 5-Year Change | -83.61% |
| Total Return (1Y) | -60.98% |
| Total Return (3Y CAGR) | -24.54% |
| Total Return (5Y CAGR) | -33.12% |
| Return vs SPY (1Y) | -75.10% |
| Max Drawdown (1Y) | -74.68% |
| Max Drawdown (3Y) | -82.08% |
| Sharpe Ratio (1Y) | -1.21 |
| Correlation with SPY (1Y) | 0.29 |
| 50-Day Average | $2.66 |
| 200-Day Average | $4.47 |
| 52-Week Range | $1.76 to $7.61 |
| RSI (14 Days) | 35.4 |
| Average Volume (20 Days) | 749.84K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 4.24x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 4.24x |
|---|---|
| Quick Ratio | 4.24x |
| Debt / Equity | 0.00x |
Returns and Efficiency
| Return on Assets (ROA) | 4.93% |
|---|---|
| ROA (5Y Average) | -29.76% |
| ROIC (5Y Average) | 60.45% |
| Asset Turnover | 0.57x |
Scores
FHTX has an Altman Z-Score of -2.63, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -2.63 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $112.13M over the last 12 months.
| Revenue | $112.13M |
|---|---|
| Revenue Growth (YoY) | +357.33% |
| Gross Profit | $112.13M |
| Operating Income | $2.38M |
| Pretax Income | $9.42M |
| Net Income | $9.42M |
| Reported EPS (TTM) | $0.04 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $80.30M |
|---|---|
| Total Debt | $0 |
| Net Cash | $80.30M |
| Net Cash Per Share | $1.12 |
| Working Capital | $121.00M |
| Shareholder Equity | -$14.08M |
| Total Assets | $190.95M |
| Total Liabilities | $205.04M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $57.00K of capital spending, operating cash flow left -$83.68M of free cash flow.
| Operating Cash Flow | -$83.62M |
|---|---|
| Capital Expenditures | $57.00K |
| Free Cash Flow | -$83.68M |
| FCF Per Share | -$1.41 |
| Depreciation and Amortization | $3.40M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 2.13%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | 2.13% |
| Pretax Margin | 8.40% |
| Net Margin | 8.40% |
| FCF Margin | -74.63% |
Growth
Revenue grew 17.14% a year over 3 years.
| Revenue Growth (3Y CAGR) | +17.14% |
|---|---|
| Revenue Growth (5Y CAGR) | +135.14% |
Dividends and Yields
FHTX does not pay a dividend.
| Earnings Yield | 2.44% |
|---|---|
| Buyback Yield | -42.81% |
| Shareholder Yield | -42.81% |
Peer Position
Against 8 similar companies, FHTX has the 7th highest P/S.
P/S RatioPeer median 3.5x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -31.54%
| P/S Ratio | 1.2x vs 3.5x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +357.33% vs -31.54% median |
Analyst Forecast
Consensus estimates put revenue growth at -55.07% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -55.07% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About FHTX
What is FHTX's market cap?
Foghorn Therapeutics has a market cap of $124.12M. Its enterprise value, which adds debt and subtracts cash, is $43.82M.
What is FHTX's P/E ratio?
Foghorn Therapeutics has a trailing P/E ratio of 41.0x.
How many shares of FHTX are outstanding?
Foghorn Therapeutics has 71.46M shares outstanding. The count is up 13.38% from a year earlier.
Does FHTX pay a dividend?
No. Foghorn Therapeutics does not pay a dividend.
How much debt does FHTX have?
Foghorn Therapeutics has $0 of total debt and $80.30M of cash and equivalents, a net cash position of $80.30M.
FHTX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors